<DOC>
	<DOCNO>NCT01998919</DOCNO>
	<brief_summary>This study evaluate efficacy safety sequential administration Tarceva gemcitabine/platinum chemotherapy patient stage IIIb/IV non-small cell lung cancer . Patients randomize receive Tarceva ( 150 mg po ) placebo day 15-28 4 week cycle intravenous platinum-based chemotherapy , total 6 cycle . The anticipated time study treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Combination With Platinum Based Chemotherapy Patients With Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically document advanced recurrent stage IIIB IV nonsmall cell lung cancer ; measurable disease ; previous chemotherapy nonsmall cell lung cancer . unstable systemic disease ; malignancy last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>